Literature DB >> 16188955

Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.

Linda B von Weymarn1, Kathryn M Brown, Sharon E Murphy.   

Abstract

Nicotine is the major addictive agent in tobacco. The primary catalyst of nicotine metabolism in humans is CYP2A6. However, the closely related enzyme CYP2A13 is a somewhat better catalyst. CYP2A13 is an extrahepatic enzyme that is an excellent catalyst of the metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK). Here we report that both CYP2A6 and CYP2A13 were inactivated during nicotine metabolism. Inactivation of both enzymes was dependent on NADPH and increased with time and concentration. Alternate substrates for CYP2A6 and CYP2A13 protected these enzymes from inactivation. Inactivation of CYP2A13 was irreversible upon extensive dialysis and seems to be mechanism-based. The K(I) of CYP2A13 inactivation by nicotine was 17 microM, the rate of inactivation, k(inact), was 0.1 min(-1), and the t(1/2) was 7 min. However, the loss in enzyme activity occurred after nicotine metabolism was complete, suggesting that a secondary or possible tertiary metabolite of nicotine may be responsible. [5-(3)H]Nicotine metabolism by CYP2A13 was monitored by radioflow high-pressure liquid chromatography during the course of enzyme inactivation; the major product was the Delta(1'(5'))iminium ion. However, cotinine was a significant metabolite even at short reaction times. The metabolism of the nicotine Delta(1'(5'))iminium ion to cotinine did not require the addition of aldehyde oxidase. CYP2A13 catalyzed this reaction as well as further metabolism of cotinine to 5'-hydroxycotinine, trans-3'-hydroxycotinine, and N-(hydroxymethyl)-norcotinine as enzyme inactivation occurred. Studies are on-going to identify the metabolite responsible for nicotine-mediated inactivation of CYP2A13.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188955     DOI: 10.1124/jpet.105.091306

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.

Authors:  Jian-Min Yuan; Heather H Nelson; Steven G Carmella; Renwei Wang; Jacquelyn Kuriger-Laber; Aizhen Jin; Jennifer Adams-Haduch; Stephen S Hecht; Woon-Puay Koh; Sharon E Murphy
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

2.  The inhibition of cytochrome P450 2A13-catalyzed NNK metabolism by NAT, NAB and nicotine.

Authors:  Xingyu Liu; Jie Zhang; Chen Zhang; Bicheng Yang; Limeng Wang; Jun Zhou
Journal:  Toxicol Res (Camb)       Date:  2016-04-28       Impact factor: 3.524

3.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

4.  Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine.

Authors:  Dongmei Li; Yong Wang; Keli Han; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-07-15       Impact factor: 2.991

5.  Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.

Authors:  Natasha M DeVore; Emily E Scott
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

6.  Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats.

Authors:  Emily M Jutkiewicz; Danielle M Nicolazzo; Myung N Kim; Margaret E Gnegy
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

7.  The pneumotoxin 3-methylindole is a substrate and a mechanism-based inactivator of CYP2A13, a human cytochrome P450 enzyme preferentially expressed in the respiratory tract.

Authors:  Jaime D'Agostino; Xiaoliang Zhuo; Mohammad Shadid; Daniel G Morgan; Xiuling Zhang; W Griffith Humphreys; Yue-Zhong Shu; Garold S Yost; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2009-07-16       Impact factor: 3.922

8.  Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Authors:  Jeannette Zinggeler Berg; Jesse Mason; Angela J Boettcher; Dorothy K Hatsukami; Sharon E Murphy
Journal:  J Pharmacol Exp Ther       Date:  2009-09-28       Impact factor: 4.030

9.  The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.

Authors:  A Joseph Bloom; Linda B von Weymarn; Maribel Martinez; Laura J Bierut; Alison Goate; Sharon E Murphy
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

10.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.